Regulatory Affairs
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Navigate global pharma regulatory affairs. Get expert insights on FDA, EMA, and global compliance for drug approvals, market access, and R&D strategy.
Showing 1–11 of 11 articles
Quick answer
NovaPharmaNews Regulatory Affairs hub for EMA covers 11 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
RAPS Euro Convergence: Key Regulatory Highlights for Pharma
RAPS Euro Convergence: Regulatory Updates & Key Takeaways
RAPS Euro Convergence 2026: Regulatory News - Day 1 Roundup
EMA Establishes Expert Panel to Strengthen COVID-19 mRNA Vaccine Trust Including Spikevax and Comirnaty
SQ Innovation's Lasix ONYU Receives CE Marking Approval, Advances Toward European Market Authorization
Zentiva Appeals EU Court Decision on Urban Wastewater Directive Affecting Generic Medicine Access
EMA Issues Positive Opinion for Redemplo (Plozasiran) in European Drug Approval Process
EMA CHMP Recommends 6 New Medicines for Approval Including Treatments for Menopause, Liver Disease, and Rare Disorders
New Additional Risk Minimization Measures (aRMMs) Training Course Launches to Enhance Pharmaceutical Patient Safety Protocols
SAHPRA and African Medicines Agency Launch Continental Pharmaceutical Regulatory Harmonization Course for May 2026
MENA Medical Device Regulatory Training Course Launches May 2026 to Address Growing Market Demand
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.